- Home
- LGVN
LGVN
Longeveron Inc.
as 04-23-2025 4:00pm EST
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | MIAMI |
| Market Cap: | 27.6M | IPO Year: | 2021 |
| Target Price: | $8.67 | AVG Volume (30 days): | 118.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.62 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.77 - $6.40 | Next Earning Date: | 05-13-2025 |
| Revenue: | $2,392,000 | Revenue Growth: | 237.38% |
| Revenue Growth (this year): | 1.3% | Revenue Growth (next year): | 19.15% |
Latest Longeveron Inc. News
LGVN Breaking Stock News: Dive into LGVN Ticker-Specific Updates for Smart Investing
GlobeNewswire
a day ago
Longeveron® Issues Letter to Shareholders Highlighting Corporate Strategy, Recent Progress and Key Priorities and Goals for 2025
MT Newswires
a month ago
Longeveron Files $70 Million Mixed Shelf
GlobeNewswire
a month ago
Longeveron® Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer’s Disease
Zacks Small Cap Research
a month ago
LGVN Announces Positive Alzheimer’s News
GlobeNewswire
a month ago
Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer’s Disease
GlobeNewswire
2 months ago
Longeveron® to Present at the 37th Annual Roth Conference
Zacks Small Cap Research
2 months ago
LGVN Well Positioned for Critical 2025
Simply Wall St.
2 months ago
Analysts Expect Breakeven For Longeveron Inc. (NASDAQ:LGVN) Before Long
Compare LGVN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LGVN Longeveron Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.